Correction: Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases.

[This corrects the article DOI: 10.1136/lupus-2018-000276.].

Crow MK, Ronnblom L. Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases. Lupus Science & Medicine 2018;5:e000276. doi: 10.1136/lupus-2018-000276

The authors want to alert readers to the following two errors identified in the published version.

At page 4 (column 1, 2nd sentence of last paragraph), the sentence should read as: “Young women (35–44 years) with SLE have a 50-fold increased risk of vascular complications…”

In Table 1, the row under the drug “Anifrolumab” states that the drug is at Phase II for Sjögren’s syndrome. This has been stated incorrectly and has been removed. The updated Table 1 is now available below:

In the legend of figure 1, the term ‘interferon-stimulating genes’ appears. The correct term is ‘interferon-stimulated genes’.

The role of IFN in viral infection over time. cDC, conventional dendritic cell; IFN, interferon; IL, interleukin; ISG, interferon-stimulated genes; pDC, plasmacytoid dendritic cells; PD-L1, programmed death ligand 1; PRR, pattern recognition receptor. Left panel adapted from Crouse J et al 9; right panel adapted from Zuniga EI et al 10 (Reprinted by permission from Springer Customer Service Centre GmbH: Springer Nature, Nature Reviews Immunology; Regulation of antiviral T cell responses by type I interferons. Crouse J, Kalinke U, Oxenius A, © 2015. Republished with permission of Annual Reviews, from Innate and Adaptive Immune Regulation During Chronic Viral Infections, Zuniga EI, Macal M, Lewis GM, et al, Vol. 2, © 2015; permission conveyed through Copyright Clearance Center).

Table 1

Therapeutic agents targeting components of the type I IFN pathway and in clinical development for IFN-driven diseases

Drug	Drug MOA	Development status	Disease
RSLV132	RNA hydrolysis	Phase II	Systemic lupus erythematosus Sjögren's syndrome
SM101	Anti–immune complex	Phase II	Systemic lupus erythematosusLupus nephritis
BIIB059	Anti-BDCA2 (pDCs)	Phase II	Systemic lupus erythematosus
MEDI-7734	Anti-ILT7 (pDCs)	Phase I	Dermatomyositis Polymyositis Systemic sclerosis Sjögren's syndrome Systemic lupus erythematosus
JNJ-55920839	Anti–IFN-α/ω	Phase I	Systemic lupus erythematosus
AGS-009	Anti–IFN-α	Phase I*	Systemic lupus erythematosus
IFN-α-kinoid	Anti–IFN-α	Phase II	Dermatomyositis
		Phase II	Systemic lupus erythematosus
Anifrolumab	Anti-IFNAR1	Phase II	Lupus nephritis
		Phase III	Systemic lupus erythematosus
Baricitinib†	JAK1/JAK2 inhibitor	Phase II	Systemic lupus erythematosus
PF-04965842	JAK1 inhibitor	Phase II	Systemic lupus erythematosus

*Development status unknown.

†European Medicines Agency approved for rheumatoid arthritis.

IFN, interferon; IFNAR1, type I interferon alpha receptor subunit 1; ILT7, immunoglobulin-like transcript 7; JAK, Janus kinase; MOA, mechanism of action; pDCs, plasmacytoid dendritic cell.